Source Post

Novo Nordisk ($NVO) vs Eli Lilly ($LLY) And Super Micro Computer ($SMCI) Drama

The RoseMar 21, 2026

The creator discusses Novo Nordisk and Eli Lilly, focusing on their competition in the GLP-1 and oral weight loss markets. The creator also touches on Super Micro Computer and an alleged scheme involving Nvidia chips.

Linked Mentions

Tickers discussed in this post

ZETABullishHigh ConvictionSignal-backedPrimary

Zeta is a stock the creator loves and is willing to average up on.

ELFBullishMedium ConvictionSignal-backedSecondary

ELF is a buying opportunity on the current dip.

NOWBullishMedium ConvictionSignal-backedSecondary

Service Now is a buying opportunity on the current dip.

DUOLNeutralLow ConvictionSignal-backedSecondary

The creator is hesitant to average down on Duolingo despite its dip, preferring other stocks.

PYPLBullishMedium ConvictionSignal-backedSecondary

PayPal has upside potential if acquired, with a potential buyout price of $65-$70 per share.

MSFTBullishMedium ConvictionSignal-backedSecondary

Microsoft is a good buy at $380, with the creator having purchased shares in multiple portfolios.

OSCRBullishHigh ConvictionSignal-backedPrimary

Oscar Health is a strong buy with a $30 price target by 2026, despite current market weakness.

NVDANeutralLow ConvictionResearch Only

Nvidia chips are mentioned as part of an alleged scheme involving Super Micro Computer.

SMCINeutralLow ConvictionSignal-backedSecondary

Super Micro Computer is mentioned in the context of alleged schemes involving Nvidia chips.

LLYNeutralMedium ConvictionSignal-backedSecondary

Eli Lilly's delayed FDA decision for its oral pill creates an opportunity for Novo Nordisk.

NVOBullishHigh ConvictionSignal-backedPrimary

Novo Nordisk is a buy due to its renewed focus on the GLP1 market and Eli Lilly's delayed FDA decision for their oral pill.

Linked Signals

Tracked calls opened from this post

ZETA
buy opened Mar 21, 2026
+48.97%
OSCR
buy opened Mar 21, 2026
+67.38%
NVO
buy opened Mar 21, 2026
+17.49%